Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta (NASDAQ:SRPT) reported progress in the Phase 1/2 multiple ascending dose study of SRP-1003 for myotonic dystrophy type 1. Cohorts 1 (1.5 mg/kg) and 2 (3 mg/kg) are complete; cohort 3 (4.5 mg/kg) is fully enrolled and ongoing. Following a positive pre-specified drug safety committee review, the study will continue dose escalation with patients currently being dosed in cohort 4 (6 mg/kg) and planned initiation of cohort 5 (12 mg/kg) in early 2026. Having reached the enrollment target, a second milestone payment of $200 million to Arrowhead will be made within 60 days.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT) after reaching the second development milestone in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy.

The milestone followed a drug safety committee review, authorization to dose escalate, and attainment of a pre-specified patient enrollment target. Arrowhead said it expects to receive the payment within 60 days. The company reported cohort 4 (6 mg/kg) accrual is nearly complete and plans to begin enrollment in cohort 5 (12 mg/kg) in Q1 2026.

Sarepta (NASDAQ:SRPT) announced FDA approval of updated prescribing information for ELEVIDYS on November 14, 2025. Key label changes include a boxed warning for acute serious liver injury (ALI) and acute liver failure (ALF), removal of the non-ambulatory indication, expanded prescriber guidance with modified corticosteroid regimens, and enhanced weekly monitoring for 3 months post-infusion. The company plans to commence a study of an enhanced sirolimus immunosuppressive regimen to address ALI/ALF risk so dosing may resume for non-ambulatory patients with FDA concurrence. ELEVIDYS has been administered to over 1,100 patients globally.

Sarepta Therapeutics (NASDAQ:SRPT) will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025. A conference call to discuss results and recent corporate developments will follow at 4:30 p.m. ET.

The event will be webcast live via the investor relations site at https://investorrelations.sarepta.com/events-presentations and a replay will be archived there for one year. Phone participants must register online to receive dial-in details and a personal PIN by auto-generated email.

Sarepta Therapeutics (NASDAQ:SRPT) will present new clinical and real-world data at the 30th World Muscle Society Congress, Oct 7–11, 2025 in Vienna.

Presentations cover delandistrogene moxeparvovec (micro-dystrophin expression, safety, cardiac outcomes, mitigation of acute liver injury), a real-world pulmonary function study of casimersen, and EMERGENE phase 3 results for bidridistrogene xeboparvovec (SRP-9003) showing SGCB expression and safety in LGMD2E/R4. Multiple investigator-led delandistrogene abstracts (including sirolimus prophylaxis) will also be presented. Abstracts will be posted on Sarepta.com after the WMS embargo.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced equity inducement grants to 8 new employees hired in Q3 2025. The grants, approved under the company's 2024 Employment Commencement Incentive Plan, consist of 49,805 restricted stock units (RSUs). These RSUs will vest over four years, with 25% vesting annually on the grant date anniversary, contingent on continued employment.

The equity awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Compensation Committee of Sarepta's Board of Directors.

Sarepta Therapeutics (NASDAQ:SRPT) has announced 25 recipients for its Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program, now in its 8th year, will award $5,000 scholarships to 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals with the condition.

The scholarship recipients were selected by an independent committee based on academic records, community involvement, personal essays, and recommendation letters. Since its inception, the program has awarded more than 150 scholarships. The program's name, Route 79, references the 79 exons of the dystrophin gene, which is linked to Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) has announced a significant refinancing of its convertible notes through privately negotiated exchange agreements. The company will exchange approximately $700 million of its 1.25% convertible senior notes due 2027 for new 4.875% convertible notes due 2030 worth $602 million, along with up to 6.7 million shares of common stock and $123.3 million in cash.

The new convertible notes have an initial conversion rate of 16.6667 shares per $1,000 principal amount, equivalent to a conversion price of approximately $60.00 per share, representing a 191.5% premium. Additionally, Sarepta entered into a private placement agreement with J. Wood Capital Advisors LLC for up to 1.4 million shares of common stock. The transactions are expected to close around August 28, 2025.